Corporate Video

Medicom Healthcare Limited (Medicom) and Famar Health Care Services Madrid (Famar) are pleased to announce the signing of an Asset Purchase Agreement (APA) for the acquisition by Medicom of the pharmaceutical dossier of BIMATOPROST 0.3 mg/mL, 3ml, preservative free eye drop solution, developed by Famar R&D. Medicom and Famar have also entered into a long term Manufacturing and Supply Agreement (MSA) with Famar being the exclusive manufacturer of this product.

This video highlights our recognized and awarded CDMO leadership in the categories of Service, Quality, Capabilities, Expertise, Reliability and Compatibility.Watch the video for a glance at our company's culture and working principles and how we integrate all our skills together to meet the needs of our customers.

Famar came in agreement with Active Biotech AB to deliver clinical trial material of the newly developed eye-drop formulation of laquinimod.Famar R&D will provide process development, scale-up, supply of material for pre-clinical local tolerance studies and clinical grade material for use in the clinical studies.
The clinical safety study is expected by H2 2021.

FAMAR as a leading European provider of Pharmaceutical Development and Manufacturing Operations is announcing the expansion into the new exciting market of full scope service providers, becoming the first Contract Services and Consulting Organization to deliver to the unmet industry need a truly fully integrated service offering, ranging from standard manufacturing operations to every non-core service/activity requiring outsourcing.

Through the commitment of its 1.700 employees, and with a network of 6 production sites, one Distribution center and 3 R&D centers in Europe, FAMAR already offers Development and Manufacturing services for more than 1.800 products in 80 international markets, with operational excellence and customer care being at the cornerstones of its long-term business-oriented partnership.

Now, building on its 70 years of industrial CDMO operations, FAMAR innovates again as CSCO offering a new, agile approach to the Pharma Consulting and Services business segment, creating keys-on-hand solutions and managing firsthand the challenges posed in this new Era to the modern Pharmaceutical Industry.


Click here to register

The coronavirus pandemic has been incredibly disruptive for all facets of life around the globe, exerting extreme pressure on practically all industry sectors and severely impacting the usual day-to-day interactions they have become accustomed to. The pharmaceutical industry has been thrust into the vanguard of this global crisis, not only in its quest to find effective vaccines or therapeutics to fight the virus but also in its responsibility to continue to manufacture life-changing and essential medicines and ensure they are delivered to patients. Even before the pandemic struck, pharma and biotech have been steadily increasing their outsourcing to contract development and manufacturing organisations (CDMOs) not only to cut costs and have access to manufacturing capacity but also to better deploy their resources and gain access to expertise in other phases of the product lifecycle. This podcast was originally aired as part of the CPHI Festival of Pharma.